Financhill
Sell
50

AHCO Quote, Financials, Valuation and Earnings

Last price:
$9.59
Seasonality move :
-4.11%
Day range:
$9.44 - $9.82
52-week range:
$8.35 - $11.90
Dividend yield:
0%
P/E ratio:
16.02x
P/S ratio:
0.40x
P/B ratio:
0.82x
Volume:
1.2M
Avg. volume:
1.7M
1-year change:
-5.32%
Market cap:
$1.3B
Revenue:
$3.3B
EPS (TTM):
$0.60

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
AHCO
AdaptHealth
$808.2M $0.24 28.73% 111.44% $13.00
AXGN
Axogen
$53.4M $0.08 17.91% -76% $25.00
CUTRQ
Cutera
-- -- -- -- --
ELMD
Electromed
$16.6M -- 13.91% -- $37.00
MYO
Myomo
$11.4M -$0.06 147.75% -20% $8.85
STXS
Stereotaxis
$7.7M -$0.07 -0.07% -20.83% $4.50
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
AHCO
AdaptHealth
$9.61 $13.00 $1.3B 16.02x $0.00 0% 0.40x
AXGN
Axogen
$17.27 $25.00 $765.8M -- $0.00 0% 4.08x
CUTRQ
Cutera
$0.02 -- $438K -- $0.00 0% 0.00x
ELMD
Electromed
$24.62 $37.00 $210.7M 32.83x $0.00 0% 3.70x
MYO
Myomo
$5.19 $8.85 $178.4M -- $0.00 0% 6.02x
STXS
Stereotaxis
$1.83 $4.50 $156.1M -- $0.00 0% 5.79x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
AHCO
AdaptHealth
55.77% 1.259 153.77% 0.91x
AXGN
Axogen
31.37% 0.673 6.53% 1.88x
CUTRQ
Cutera
-- -3.861 -- --
ELMD
Electromed
-- 1.614 -- 4.68x
MYO
Myomo
-- 2.236 -- 2.82x
STXS
Stereotaxis
-- 1.401 -- 0.74x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
AHCO
AdaptHealth
$930.9M $76.7M 2.52% 6% 6.81% $73.1M
AXGN
Axogen
$37.6M $2M -6.89% -10.21% 4.56% $7.9M
CUTRQ
Cutera
-- -- -- -- -- --
ELMD
Electromed
$12.6M $2.5M 15.91% 15.91% 15.64% $2.9M
MYO
Myomo
$8.6M -$245.3K -48.64% -48.64% -2.03% $2.5M
STXS
Stereotaxis
$3.2M -$7.6M -139.2% -139.2% -120.3% -$4.3M

AdaptHealth vs. Competitors

  • Which has Higher Returns AHCO or AXGN?

    Axogen has a net margin of 3.41% compared to AdaptHealth's net margin of 0.91%. AdaptHealth's return on equity of 6% beat Axogen's return on equity of -10.21%.

    Company Gross Margin Earnings Per Share Invested Capital
    AHCO
    AdaptHealth
    63.15% $0.34 $3.6B
    AXGN
    Axogen
    76.06% $0.01 $151.4M
  • What do Analysts Say About AHCO or AXGN?

    AdaptHealth has a consensus price target of $13.00, signalling upside risk potential of 35.28%. On the other hand Axogen has an analysts' consensus of $25.00 which suggests that it could grow by 44.76%. Given that Axogen has higher upside potential than AdaptHealth, analysts believe Axogen is more attractive than AdaptHealth.

    Company Buy Ratings Hold Ratings Sell Ratings
    AHCO
    AdaptHealth
    5 3 0
    AXGN
    Axogen
    4 0 0
  • Is AHCO or AXGN More Risky?

    AdaptHealth has a beta of 1.302, which suggesting that the stock is 30.157% more volatile than S&P 500. In comparison Axogen has a beta of 1.024, suggesting its more volatile than the S&P 500 by 2.388%.

  • Which is a Better Dividend Stock AHCO or AXGN?

    AdaptHealth has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Axogen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AdaptHealth pays -- of its earnings as a dividend. Axogen pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios AHCO or AXGN?

    AdaptHealth quarterly revenues are $1.5B, which are larger than Axogen quarterly revenues of $49.4M. AdaptHealth's net income of $50.3M is higher than Axogen's net income of $450K. Notably, AdaptHealth's price-to-earnings ratio is 16.02x while Axogen's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AdaptHealth is 0.40x versus 4.08x for Axogen. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AHCO
    AdaptHealth
    0.40x 16.02x $1.5B $50.3M
    AXGN
    Axogen
    4.08x -- $49.4M $450K
  • Which has Higher Returns AHCO or CUTRQ?

    Cutera has a net margin of 3.41% compared to AdaptHealth's net margin of --. AdaptHealth's return on equity of 6% beat Cutera's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    AHCO
    AdaptHealth
    63.15% $0.34 $3.6B
    CUTRQ
    Cutera
    -- -- --
  • What do Analysts Say About AHCO or CUTRQ?

    AdaptHealth has a consensus price target of $13.00, signalling upside risk potential of 35.28%. On the other hand Cutera has an analysts' consensus of -- which suggests that it could grow by 9116.59%. Given that Cutera has higher upside potential than AdaptHealth, analysts believe Cutera is more attractive than AdaptHealth.

    Company Buy Ratings Hold Ratings Sell Ratings
    AHCO
    AdaptHealth
    5 3 0
    CUTRQ
    Cutera
    0 0 0
  • Is AHCO or CUTRQ More Risky?

    AdaptHealth has a beta of 1.302, which suggesting that the stock is 30.157% more volatile than S&P 500. In comparison Cutera has a beta of 1.358, suggesting its more volatile than the S&P 500 by 35.755%.

  • Which is a Better Dividend Stock AHCO or CUTRQ?

    AdaptHealth has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cutera offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AdaptHealth pays -- of its earnings as a dividend. Cutera pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios AHCO or CUTRQ?

    AdaptHealth quarterly revenues are $1.5B, which are larger than Cutera quarterly revenues of --. AdaptHealth's net income of $50.3M is higher than Cutera's net income of --. Notably, AdaptHealth's price-to-earnings ratio is 16.02x while Cutera's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AdaptHealth is 0.40x versus 0.00x for Cutera. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AHCO
    AdaptHealth
    0.40x 16.02x $1.5B $50.3M
    CUTRQ
    Cutera
    0.00x -- -- --
  • Which has Higher Returns AHCO or ELMD?

    Electromed has a net margin of 3.41% compared to AdaptHealth's net margin of 12.11%. AdaptHealth's return on equity of 6% beat Electromed's return on equity of 15.91%.

    Company Gross Margin Earnings Per Share Invested Capital
    AHCO
    AdaptHealth
    63.15% $0.34 $3.6B
    ELMD
    Electromed
    77.68% $0.22 $43.6M
  • What do Analysts Say About AHCO or ELMD?

    AdaptHealth has a consensus price target of $13.00, signalling upside risk potential of 35.28%. On the other hand Electromed has an analysts' consensus of $37.00 which suggests that it could grow by 50.28%. Given that Electromed has higher upside potential than AdaptHealth, analysts believe Electromed is more attractive than AdaptHealth.

    Company Buy Ratings Hold Ratings Sell Ratings
    AHCO
    AdaptHealth
    5 3 0
    ELMD
    Electromed
    2 0 0
  • Is AHCO or ELMD More Risky?

    AdaptHealth has a beta of 1.302, which suggesting that the stock is 30.157% more volatile than S&P 500. In comparison Electromed has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.696%.

  • Which is a Better Dividend Stock AHCO or ELMD?

    AdaptHealth has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AdaptHealth pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios AHCO or ELMD?

    AdaptHealth quarterly revenues are $1.5B, which are larger than Electromed quarterly revenues of $16.3M. AdaptHealth's net income of $50.3M is higher than Electromed's net income of $2M. Notably, AdaptHealth's price-to-earnings ratio is 16.02x while Electromed's PE ratio is 32.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AdaptHealth is 0.40x versus 3.70x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AHCO
    AdaptHealth
    0.40x 16.02x $1.5B $50.3M
    ELMD
    Electromed
    3.70x 32.83x $16.3M $2M
  • Which has Higher Returns AHCO or MYO?

    Myomo has a net margin of 3.41% compared to AdaptHealth's net margin of -2.16%. AdaptHealth's return on equity of 6% beat Myomo's return on equity of -48.64%.

    Company Gross Margin Earnings Per Share Invested Capital
    AHCO
    AdaptHealth
    63.15% $0.34 $3.6B
    MYO
    Myomo
    71.39% -$0.01 $24.7M
  • What do Analysts Say About AHCO or MYO?

    AdaptHealth has a consensus price target of $13.00, signalling upside risk potential of 35.28%. On the other hand Myomo has an analysts' consensus of $8.85 which suggests that it could grow by 70.52%. Given that Myomo has higher upside potential than AdaptHealth, analysts believe Myomo is more attractive than AdaptHealth.

    Company Buy Ratings Hold Ratings Sell Ratings
    AHCO
    AdaptHealth
    5 3 0
    MYO
    Myomo
    3 0 0
  • Is AHCO or MYO More Risky?

    AdaptHealth has a beta of 1.302, which suggesting that the stock is 30.157% more volatile than S&P 500. In comparison Myomo has a beta of 1.609, suggesting its more volatile than the S&P 500 by 60.902%.

  • Which is a Better Dividend Stock AHCO or MYO?

    AdaptHealth has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AdaptHealth pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios AHCO or MYO?

    AdaptHealth quarterly revenues are $1.5B, which are larger than Myomo quarterly revenues of $12.1M. AdaptHealth's net income of $50.3M is higher than Myomo's net income of -$260.1K. Notably, AdaptHealth's price-to-earnings ratio is 16.02x while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AdaptHealth is 0.40x versus 6.02x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AHCO
    AdaptHealth
    0.40x 16.02x $1.5B $50.3M
    MYO
    Myomo
    6.02x -- $12.1M -$260.1K
  • Which has Higher Returns AHCO or STXS?

    Stereotaxis has a net margin of 3.41% compared to AdaptHealth's net margin of -118.53%. AdaptHealth's return on equity of 6% beat Stereotaxis's return on equity of -139.2%.

    Company Gross Margin Earnings Per Share Invested Capital
    AHCO
    AdaptHealth
    63.15% $0.34 $3.6B
    STXS
    Stereotaxis
    50.73% -$0.09 $11.4M
  • What do Analysts Say About AHCO or STXS?

    AdaptHealth has a consensus price target of $13.00, signalling upside risk potential of 35.28%. On the other hand Stereotaxis has an analysts' consensus of $4.50 which suggests that it could grow by 145.9%. Given that Stereotaxis has higher upside potential than AdaptHealth, analysts believe Stereotaxis is more attractive than AdaptHealth.

    Company Buy Ratings Hold Ratings Sell Ratings
    AHCO
    AdaptHealth
    5 3 0
    STXS
    Stereotaxis
    2 0 0
  • Is AHCO or STXS More Risky?

    AdaptHealth has a beta of 1.302, which suggesting that the stock is 30.157% more volatile than S&P 500. In comparison Stereotaxis has a beta of 1.546, suggesting its more volatile than the S&P 500 by 54.601%.

  • Which is a Better Dividend Stock AHCO or STXS?

    AdaptHealth has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stereotaxis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AdaptHealth pays -- of its earnings as a dividend. Stereotaxis pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios AHCO or STXS?

    AdaptHealth quarterly revenues are $1.5B, which are larger than Stereotaxis quarterly revenues of $6.3M. AdaptHealth's net income of $50.3M is higher than Stereotaxis's net income of -$7.5M. Notably, AdaptHealth's price-to-earnings ratio is 16.02x while Stereotaxis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AdaptHealth is 0.40x versus 5.79x for Stereotaxis. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AHCO
    AdaptHealth
    0.40x 16.02x $1.5B $50.3M
    STXS
    Stereotaxis
    5.79x -- $6.3M -$7.5M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Reddit a Buy on the Dip?
Is Reddit a Buy on the Dip?

Reddit (NYSE:RDDT) share price has been on the proverbial ropes…

Qualcomm Stock: 5G Leader at a Bargain Price?
Qualcomm Stock: 5G Leader at a Bargain Price?

Chip giant QUALCOMM Incorporated (NASDAQ:QCOM) was the ultimate chip company…

What Is Buffett Buying and Selling Now?
What Is Buffett Buying and Selling Now?

In Q4 of last year, Warren Buffett made a few…

Stock Ideas

Buy
52
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
56
Is NVDA Stock a Buy?

Market Cap: $3T
P/E Ratio: 41x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Buy
59
GRRR alert for Mar 15

Gorilla Technology Group [GRRR] is up 29.72% over the past day.

Sell
49
SMTC alert for Mar 15

Semtech [SMTC] is up 21.28% over the past day.

Buy
62
PLPC alert for Mar 15

Preformed Line Products [PLPC] is up 17.38% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock